Rigel Pharmaceuticals Inc
$ 32.43
2.08%
17 Apr - close price
- Market Cap 599,307,000 USD
- Current Price $ 32.43
- High / Low $ 33.17 / 32.00
- Stock P/E 1.66
- Book Value 21.38
- EPS 19.48
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.23 %
- ROE 1.86 %
- 52 Week High 52.24
- 52 Week Low 16.43
About
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$51.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-04 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.1198 | 1.46 | 3.28 | 0.63 | 0.8 | 0.7 | -0.06 | -0.05 | 0.0042 | -0.03 | -0.04 | -0.08 |
| Estimated EPS | 1.2015 | 0.01 | -0.03 | 0.0893 | 0.5789 | 0.06 | -0.29 | -0.03 | -0.03 | -0.07 | -0.08 | -0.1 |
| Surprise | -0.0817 | 1.45 | 3.31 | 0.5407 | 0.2211 | 0.64 | 0.23 | -0.02 | 0.0342 | 0.04 | 0.04 | 0.02 |
| Surprise Percentage | -6.7998% | 14500% | 11033.3333% | 605.4871% | 38.1931% | 1066.6667% | 79.3103% | -66.6667% | 114% | 57.1429% | 50% | 20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.86 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RIGL
2026-04-13 09:09:22
Ritholtz Wealth Management significantly increased its stake in Rigel Pharmaceuticals (NASDAQ:RIGL) by 961.3% in the fourth quarter, acquiring an additional 72,999 shares, bringing their total to 80,593 shares valued at approximately $3.45 million. The biotechnology company, with a market capitalization of $539.6 million, has a "Moderate Buy" consensus rating and a target price of $45.67 from analysts, despite missing EPS estimates in its latest quarterly report. Insider insider Walter H. Moos recently sold 4,000 shares, reducing his holdings by almost 24%.
2026-04-12 13:40:31
Ritholtz Wealth Management has significantly increased its stake in Rigel Pharmaceuticals (NASDAQ:RIGL) by 961.3% through the acquisition of an additional 72,999 shares. This investment reflects the firm's confidence in the biotechnology company's specialized pharmaceutical manufacturing capabilities and future prospects. Rigel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for immune, hematologic, and oncologic diseases.
2026-04-09 06:39:20
Rigel Pharmaceuticals is projecting strong revenue growth for 2025, targeting between $200 million and $210 million, following a robust first-quarter performance. This outlook suggests confidence in their product pipeline and market penetration. The company's financial health appears to be on an upward trajectory.
2026-04-09 05:09:00
Rigel Pharmaceuticals is transitioning from a research-driven company to a commercially focused entity in hematology and oncology, bolstered by recent acquisitions and strong revenue growth. Despite a recent earnings miss, management projects positive net income for 2026, creating a disconnect with the stock's current low P/E ratio. Analysts maintain a "Moderate Buy" rating with significant upside potential, depending on the company's ability to execute its commercial strategy and advance its pipeline.
2026-04-09 04:10:11
Rigel Pharmaceuticals is projecting strong revenue growth in 2025, targeting $200 million to $210 million, reflecting confidence in its product pipeline and market position. This positive outlook follows a robust first-quarter performance, indicating momentum for the company. The pharmaceutical firm appears optimistic about its future financial results.
2026-04-09 02:10:01
Rigel Pharmaceuticals is experiencing a dichotomy of strong institutional interest and solid fundamentals against weak technical indicators and divided analyst opinions. While large investors are accumulating shares, suggesting potential long-term bullishness, the technical charts warn of volatility and a lack of clear direction. Investors are advised to monitor upcoming earnings and clinical catalysts before committing capital.
